转移性结直肠癌序贯治疗与联合治疗的3期试验:C-cubed研究
本研究纳入300例既往未治疗的转移性结直肠癌患者,随机接受氟嘧啶联合贝伐珠单抗序贯治疗(n=151)或氟嘧啶联合奥沙利铂及贝伐珠单抗联合治疗(n=149)。序贯治疗策略失败时间显著优于联合治疗(15.2个月 vs 7.8个月,P<0.001),但中位总生存无显著差异(27.5个月 vs 27.0个月,HR 0.92,P=0.61)。
要点
- 序贯治疗策略失败时间15.2个月,优于联合治疗的7.8个月(P<0.001)。
- 两组中位总生存无显著差异:序贯组27.5个月 vs 联合组27.0个月(HR 0.92,P=0.61)。
- 客观缓解率序贯组33.1%,联合组51.7%。
核心结论
- 研究结果支持将氟嘧啶联合贝伐珠单抗起始的序贯治疗扩展至不需要对威胁性疾病取得客观缓解的选定患者。
研究设计与样本
- 3期随机对照试验,纳入300例既往未治疗的转移性结直肠癌患者,随机分为序贯治疗组(n=151)和联合治疗组(n=149)。
- 序贯治疗为氟嘧啶联合贝伐珠单抗,疾病进展时推荐升级为氟嘧啶联合奥沙利铂及贝伐珠单抗;联合治疗为氟嘧啶联合奥沙利铂及贝伐珠单抗。
- 主要终点为策略失败时间,次要终点包括总生存、无进展生存、客观缓解率和安全性。
主要发现
- 序贯治疗组策略失败时间15.2个月(95%CI 12.5-17.2个月)vs 联合治疗组7.8个月(95%CI 6.3-9.5个月),P<0.001。
- 序贯治疗组中位总生存27.5个月(95%CI 24.4-32.7个月)vs 联合治疗组27.0个月(95%CI 22.8-36.0个月),HR 0.92(95%CI 0.66-1.28),P=0.61。
- 序贯治疗组客观缓解率33.1%,联合治疗组客观缓解率51.7%。
临床怎么用
- 原文结论指出,研究结果支持将氟嘧啶联合贝伐珠单抗起始的序贯治疗扩展至不需要对威胁性疾病取得客观缓解的选定患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the addition of oxaliplatin at first progression was better than a combination treatment using fluoropyrimidines and oxaliplatin with bevacizumab. METHODS: In the sequential treatment, the escalation from fluoropyrimidines plus bevacizumab to fluoropyrimidines plus oxaliplatin with bevacizumab was recommended in case of progressive disease. Time to failure of strategy was the primary end-point, whereas the secondary end-points were overall survival, progression-free survival, overall response rate and safety. RESULTS: Three hundred patients with previously untreated metastatic colorectal cancer were randomised to receive either the sequential treatment (n = 151) or the combination treatment (n = 149). The sequential treatment was superior to the combination treatment about time to failure of strategy (15.2 months; 95% CI, 12.5-17.2 months vs. 7.8 months: 95% CI, 6.3-9.5 months; P < 0.001). However, the median overall survival was 27.5 (95% CI, 24.4 to 32.7) months in the sequential treatment and 27.0 (95% CI, 22.8 to 36.0) months in the combination treatment (hazard ratio, 0.92; 95% CI, 0.66 to 1.28; P = 0.61). The overall response rate was 33.1% in the sequential treatment arm and 51.7% in the combination treatment. CONCLUSIONS: The findings support the extension of the sequential treatment starting from fluoropyrimidine plus bevacizumab to selected patients who do not need an objective response to the threatening disease.
引用
- Inada R, Nagasaka T, Shimokawa M, et al. Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. Eur J Cancer. 2022. PMID: 35569283. doi:10.1016/j.ejca.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。